Business
Precigen Triple-Gene Provides Six-month Follow-up Data from Phase I Study of INXN-4001, a Multigenic Investigational Therapeutic Candidate for Heart Failure
- INXN-4001 delivered via retrograde coronary sinus infusion was well-tolerated in patients with chronic heart failure - - Preliminary data suggest an overall
About this update from Precigen, Inc.
[{"type":"text","content":"- INXN-4001 delivered via retrograde coronary sinus infusion was well-tolerated in patients with chronic heart failure -\n - Preliminary data suggest an overall improvement in patient reported outcomes in 50% of patients six months after treatment -\n\n\nGERMANTOWN, Md., Aug. 6, 2020 /PRNewswire/ -- Precigen Triple-Gene, a clinical stage cardiovascular gene therapy company and majority-owned subsidiary of Precigen, Inc. (Nasdaq: PGEN), today announced six-month follow-up data from the Phase I trial of INXN-4001 (clinical trial identifier: NCT03409627), a multigenic investigational therapeutic candidate under evaluation for the treatment of heart failure. The INXN-4001 investigational therapy uses a non-viral plasmid designed to constitutively express human SDF-1α, VEGF165, and S100A1 gene products, which affect progenitor cell recruitment, angiogenesis, and calcium handling, respectively. INXN-4001 is designed to target the underlying molecular mechanisms of pathological myocardial remodelling and is delivered to the ventricle via retrograde coronary sinus infusion (RCSI). \n\n \n \n \n \n \n \n\n \nThe primary objectives of the Phase I study are to evaluate the safety of INXN-4001 infusion into the myocardium of left ventricular assist device (LVAD) patients and to demonstrate safety and feasibility of RCSI. Secondary endpoints include improvements in 6-min walk test (6MWT) duration and distance and quality of life, as assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ) responses.\nTwelve chronic heart failure patients were treated with INXN-4001 in either Cohort 1 (80 mg/40 ml; n=6) or Cohort 2 (80 mg/80 mL; n=6) and 10 were evaluated for six-month follow-up. The study has met the primary endpoints to evaluate safety and feasibility for INXN-4001. The infusions of INXN-4001 were overall well tolerated, with no adverse events attributed to INXN-4001, whereas one serious adverse event was considered related to the infusion procedure. \nFurthermore, preliminary assessment of the secondary endpoints show improvement by at least five points in total KCCQ score, a validated tool qualified by the FDA for Clinical Outcome Assessment, was observed in 50% of patients evaluable (5 out of 10) at the six-month follow-up visit. These included four patients treated in Cohort 1 and one patient treated in Cohort 2. Of the evaluable pat...